14 March 2016


(“Sareum” or the “Company”)

Issue of Options

The Company announces that it granted on 11 March 2016 the following share options (the “Options”) to Tim Mitchell, Chief Executive Officer, John Reader, Chief Scientific Officer and Paul Harper, Non-Executive Chairman;


Number of options

Tim Mitchell


John Reader


Paul Harper


The Options have been granted with an exercise price of 0.59 pence and are exercisable until 12 March 2026. The Options will vest subject to pre-determined performance criteria.

In addition to the Options being granted, Tim Mitchell and John Reader currently each hold the following options:

Exercise period

Number of options

Exercise price

4 December 2009 - 4 December 2019


0.25 pence

22 December 2010 - 22 December 2020


0.26 pence

13 March 2012 - 13 March 2022


1.2 pence

18 December 2013 – 18 December 2023


0.6 pence

25 November 2014 – 25 November 2024


0.425 pence

In addition to the Options being granted, Paul Harper holds the following options:

Exercise period

Number of options

Exercise price

18 December 2013 – 18 December 2023


0.6 pence

25 November 2014 – 25 November 2024


0.425 pence


Sareum Holdings plc


Tim Mitchell

01223 497 700

WH Ireland Limited (Nominated Adviser and Co-Broker)

Chris Fielding / Nick Prowting

020 7220 1666

Hybridan LLP (Co-Broker)


Claire Noyce / William Lynne

020 3764 2341/2342

The Communications Portfolio (Media enquiries)


Ariane Comstive

07785 922 354

Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers. Its research pipeline includes a programme awaiting final approval to start clinical trials and another undergoing pre-clinical IND-enabling studies.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and autoimmune disease research programmes. SKIL® can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR. For further information, please visit www.sareum.co.uk


  • @Sareumplc Latest tweet

    RT @HybridanLLP: Good to see Sareum's research on TYK2 as an oncology target referenced here. We see Sareum as a frontrunner in this space… via @Sareumplc
    View more